New York Mesothelioma Lawyer Applauds Advances in Gene Therapy Cited in New Book
Attorney Joseph W. Belluck of New York´s Belluck & Fox, LLP, says a new history of gene therapy presents an optimistic outlook for the future of fighting asbestos exposure diseases.
New York, NY (PRWEB) April 19, 2012
New York mesothelioma lawyer Joseph W. Belluck said today that a new book about gene therapy is another sign of hope for mesothelioma sufferers.
Belluck, a founding partner of the New York personal injury firm, Belluck & Fox, LLP, said that the book, The Forever Fix: Gene Therapy and the Boy Who Saved It, presents an optimistic look at the history and future of gene therapy as a means of fighting a variety of diseases.
“Advances in gene therapy have benefitted mesothelioma patients already and, we expect, they will prove even more beneficial in the future,” Belluck said.
Publishers Weekly recently called the book an “impressive, meticulously researched study of the exciting new developments in gene therapy.”
Belluck noted that clinical trial results recently released by Dr. Daniel Sterman and the University of Pennsylvania School of Medicine also cited advances against mesothelioma through gene therapy.
Sterman discussed the research last month as part of the Mesothelioma Applied Research Foundation´s “Meet the Experts” series. He said that gene therapy and chemotherapy combined can shrink mesothelioma tumors at twice the rate of traditional treatments.
Mesothelioma is a cancer of the lining of the chest and abdomen caused by exposure to asbestos, a naturally occurring heat- and fire-resistant fibrous mineral. Asbestos has been used in a variety of industrial machinery and equipment, and in consumer products.
Mesothelioma victims typically show disease symptoms years or even decades after exposure to asbestos in an industrial or manufacturing workplace. The disease is eventually fatal, but aggressive therapy may prolong the lives of patients who are diagnosed early.
Belluck is a nationally recognized attorney whose practice focuses on litigation of mesothelioma and other asbestos-exposure cases. He has won several major personal injury and wrongful death lawsuits involving injuries from asbestos exposure.
“At Belluck & Fox, we will continue to support gene therapy research just as we will continue to support victims of mesothelioma and other asbestos exposure diseases,” Belluck said.
About Belluck & Fox, LLP
Belluck & Fox, LLP, is a nationally recognized law firm that represents individuals with asbestos and mesothelioma claims, as well as victims of crime, motorcycle crashes, lead paint and other serious injuries. The firm provides personalized and professional representation and has won over $400 million in compensation for clients and their families.
Partner Joseph W. Belluck is AV-rated by Martindale-Hubbell and is listed in Best Lawyers in America, New York Magazine´s “Best Lawyers in the New York Area” and in Super Lawyers. Mr. Belluck has won numerous cases involving injuries from asbestos, defective medical products, tobacco and lead paint, including a recent asbestos case that settled for more than $12 million.
Partner Jordan Fox is a well-known asbestos and mesothelioma attorney who has been named to the Best Lawyers in America, New York Magazine´s “Best Lawyers in the New York Area” and to Super Lawyers. On two separate occasions his verdicts were featured as the National Law Journal´s Largest Verdict of the Year. He recently secured verdicts of $32 million and more than $19 million on behalf of individuals who had contracted mesothelioma from asbestos exposure.
In September, Belluck & Fox, LLP, won a coveted spot on a list of America’s best law firms, which was published jointly by U.S. News & World Report and Best Lawyers magazine. The listing showcased 8,782 different law firms ranked in one or more of 81 major practice areas.
For more information, contact the firm at (877) 637-6843 or through the online contact form.
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebny-mesothelioma-lawyer/gene-therapy-advances/prweb9396854.htm